Monte Rosa Therapeutics financials
$11.74+0.26%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.0M | $4.2M | $2.8M | $12.8M | $23.2M | $84.9M | $60.6M | $9.2M | $4.7M | $1.1M | $0.00 | $0.00 |
| Gross profit | $9.0M | $4.2M | $2.8M | $12.8M | $23.2M | $84.9M | $60.6M | $9.2M | $4.7M | $1.1M | $0.00 | $0.00 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — | — |
| Operating income | -$49.1M | -$50.0M | -$49.7M | -$33.0M | -$15.6M | $44.0M | $13.0M | -$26.5M | -$32.6M | -$34.9M | -$34.9M | -$37.0M |
| Net income | -$43.4M | -$44.5M | -$46.1M | -$27.1M | -$12.3M | $46.9M | $13.4M | -$23.9M | -$30.3M | -$32.0M | -$33.3M | -$34.9M |
| Net margin | −483.9% | −1057.1% | −1658.9% | −212.1% | −53.0% | 55.2% | 22.2% | −258.9% | −645.6% | −3004.5% | — | — |
| Diluted EPS | $-0.43 | $-0.45 | $-0.54 | $-0.33 | $-0.15 | $0.57 | $0.16 | $-0.29 | $-0.43 | $-0.53 | $-0.58 | $-0.70 |
| EBITDA | -$47.2M | -$48.0M | -$47.6M | -$30.9M | -$13.4M | $46.1M | $15.1M | -$24.4M | -$30.6M | -$33.0M | -$33.0M | -$35.1M |
| Operating cash flow | -$44.1M | -$37.4M | -$43.0M | $100.4M | -$34.7M | -$45.5M | $128.9M | -$21.0M | -$27.8M | -$38.2M | $29.6M | -$24.7M |
| Free cash flow | -$48.8M | -$39.2M | -$43.8M | $99.8M | -$36.4M | -$47.1M | $128.7M | -$21.4M | -$29.8M | -$39.5M | $27.9M | -$26.4M |
| Diluted shares | 101.5M | 99.9M | 84.7M | 82.4M | 82.2M | 83.0M | 82.2M | 82.0M | 71.2M | 60.2M | 57.0M | 49.8M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $90.1M | $159.9M | $129.9M | $208.3M | $69.4M | $78.5M |
| Short-term investments | $531.0M | $506.4M | $247.2M | $182.9M | $221.2M | $247.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $691.2M | $736.4M | $448.7M | $459.8M | $359.6M | $393.2M |
| Total liabilities | $203.9M | $214.5M | $215.6M | $214.0M | $91.5M | $118.0M |
| Shareholders' equity | $487.3M | $521.9M | $233.1M | $245.8M | $268.1M | $275.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology